ALUNBRIG SMART™: A FREE TRIAL PROGRAM

The ALUNBRIG SMART™ Program can help you and your patients with ALK+ metastatic NSCLC assess whether ALUNBRIG is right for them by offering a 1-month free trial.

  • To get your eligiblea patients started, simply download and complete the ALUNBRIG SMART™ Program Request Form, then fax it to 1-844-269-3038. If you have any questions, call 1-844-817-6468 for assistance. It may take up to 3 days after receiving your request until the product is shipped to your patient.
  • Your patients will receive a 1-month trial of ALUNBRIG at no cost, regardless of their insurance coverage. These will be available in 30-, 90-, and 180-mg tablets so that you can select the 1-month trial at the dosage that best suits your needs.
  • Eligible patients must have an ICD-10 code verifying the diagnosis of ALK+ metastatic NSCLC, be a new patient not currently using ALUNBRIG, and not have been previously enrolled in the ALUNBRIG SMART™ Program. Additional terms apply.

There is no obligation to continue the use of ALUNBRIG after the free trial has been completed.
If you decide ALUNBRIG is right for your patients, a prescription will need to be written.

aReview patient eligibility criteria—certain restrictions apply.

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue >
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue >
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue >
Close

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel
Close

In Vitro: ALUNBRIG Inhibited 17
ALK-Inhibitor-Resistant Mutations1,2

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.

 

We use cookies to gather web statistics that help us improve our site. We store no personal details.
ACCEPT

Read More